Discontinuation of Donepezil in Advanced Dementia

Evidence for Safe Discontinuation

The Mayo Clinic guidelines recommend that donepezil can be safely tapered to discontinuation, especially in advanced dementia where there is perceived lack of benefit or when adverse effects outweigh benefits 1
Donepezil lacks long-term benefit, particularly in advanced dementia, and is indicated only for mild to moderate dementia, not severe disease 1
Common adverse effects of donepezil include nausea, vomiting, diarrhea, nightmares, and bradyarrhythmias 1

The recommended approach is gradual tapering rather than abrupt cessation to avoid potential rebound worsening of cognitive or behavioral symptoms and to minimize withdrawal-related adverse effects 2, 3
A reasonable tapering schedule would be to reduce the dose by half for 2-4 weeks, then discontinue, with monitoring for increased agitation during the first few weeks 4, 5, 2

The evidence shows that donepezil provides only modest, statistically significant but not clinically important benefits, with an average improvement on the ADAS-Cog scale of -2.02 to -2.92 points 4, 5
Benefits are maintained for only 21-81 weeks before gradual deterioration resumes, and most studies did not demonstrate statistical significance for clinically important individual responses 4, 5

The American College of Physicians and other guideline societies implicitly support the decision to discontinue donepezil in advanced dementia by not recommending its use in severe disease, and the Mayo Clinic guidelines explicitly state that it is safe to taper to off 1
Monitor for acute worsening of cognition or behavior, increased agitation or neuropsychiatric symptoms, and changes in functional status after discontinuation 2, 3